Opinion|Videos|December 30, 2024
Improving Transitions of Care for Patients Receiving Bispecific Therapies and Final Recommendations
Key Takeaways
- Weekly dosing may provide consistent therapeutic levels, while biweekly dosing reduces hospital visits, affecting patient convenience and healthcare resource allocation.
- Formulary decisions should evaluate efficacy, safety profiles, cost-effectiveness, and integration potential into existing treatment regimens.
Panelists discuss how key recommendations for optimizing bispecific therapy care focus on establishing robust communication protocols between academic and community centers while ensuring community centers develop comprehensive infrastructure including staff training, emergency protocols, and care coordination pathways.
Advertisement
Episodes in this series
Video content above is prompted by the following
- What recommendations do you have for improving the transitions of care between academic and community centers for patients receiving bispecific therapies?
- What additional recommendations do you have for community centers building a bispecific therapy program?
Advertisement
Related to this article
Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
October’s hematology coverage highlighted first-line pirtobrutinib, questions about myeloma treatment duration and early intervention, and pharmacists’ roles in medication safety and access.
October’s oncology coverage highlighted new treatment options in rectal, breast, and prostate cancers, alongside longer-term survival findings and concerns about reduced-frequency immunotherapy.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
ESMO 2026 lung cancer trials reshape first-line care with tarlatamab maintenance, stronger KRAS G12C results, and TROP2 ADC gains, raising pharmacy monitoring demands.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Nicotine Vaping Linked to Lower Vascular Function in Young Adults
4
Over Half of RSV-Related Deaths in Hospitalized Adults Occur After Discharge
5